Allergan’s business segments
As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and its business is classified into three segments:
- US Specialized Therapeutics
- US General Medicine
The chart below compares the segment-wise revenues for Allergan since 1Q17.
US Specialized Therapeutics segment
Allergan’s US Specialized Therapeutics segment includes its revenues from the US sales of products related to eye care, medical aesthetics, medical dermatology, neuroscience, and urology. Allergan’s US Specialized Therapeutics business revenues rose 6.5% to $1.6 billion during 1Q18, compared to $1.5 billion during 1Q17. This growth was driven by new acquisitions and increased sales of key brands.
US General Medicine segment
The US General Medicine business includes revenues from the sales of general products related to the central nervous system, women’s health, and gastroenterology, as well as anti-infectives and diversified brands.
The US General Medicine segment’s revenues fell 9.1% to $1.2 billion during 1Q18, compared to $1.3 billion during 1Q17. This decrease was driven by lower sales of central nervous system products, women’s health products, and products from its diversified brands portfolio.
Allergan’s International business includes the revenues from sales outside the US markets. These revenues include Botox therapeutics products, eye care products, medical aesthetics products, and other products.
Revenues from the company’s International segment rose 17.2% to $864.0 million during 1Q18, compared to $737.0 million during 1Q17. This includes 9.0% growth in revenues at constant exchange rates and an 8.2% positive impact of foreign exchange during 1Q18.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!